|
Daily Medical Update
Contrast-associated acute kidney injury
Friday, September 18, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP (2026) - Meta-analysis
Key Findings
- Across 49 studies, oral NAC did not reduce AKI incidence versus control (OR 1.00; 95% CI 0.90-1.11; p=0.98).
- Intravenous NAC likewise did not significantly reduce AKI (OR 0.84; 95% CI 0.67-1.04; p=0.19), hemodialysis, or mortality.
- Neither oral nor intravenous NAC reduced the risk of contrast-induced nephropathy.
📋 Practice Implication: Routine oral or intravenous NAC prophylaxis is not supported by this meta-analysis; avoid adding NAC solely to prevent CA-AKI when standard preventive care is being provided.
|
BMC nephrology (2025) - Systematic review and meta-analysis
Key Findings
- Across 11 trials involving 2,837 patients, nicorandil reduced CIN incidence versus control (RR 0.37; 95% CI 0.27-0.49; p<0.001).
- Nicorandil reduced the rise in serum creatinine at 24, 48, and 72 hours, with mean differences of -4.45, -5.57, and -5.70 micromol/L, respectively.
- Nicorandil did not significantly improve eGFR at 24, 48, or 72 hours, and did not reduce major adverse events or urgent dialysis.
📋 Practice Implication: Nicorandil is a promising adjunct for coronary-intervention patients at risk of CA-AKI, although this pooled evidence supports creatinine-based benefit more clearly than eGFR or other hard clinical outcomes.
|
Circulation. Cardiovascular interventions (2026) - Randomized controlled trial
Key Findings
- CA-AKI occurred in 19.8% of controls versus 10.9% with conventional-dose nicorandil and 8.7% with high-dose nicorandil (p<0.001).
- The observed relative risk reduction was 50% with conventional-dose nicorandil and 61% with high-dose nicorandil.
📋 Practice Implication: For PCI patients with renal dysfunction, peri-procedural oral nicorandil, particularly 10 mg three times daily in this trial, could be considered as adjunctive prophylaxis pending confirmation of longer-term benefit.
|
Arquivos brasileiros de cardiologia (2026) - Systematic review and meta-analysis
Key Findings
- In 274,102 patients with chronic kidney disease, ultra-low-contrast PCI reduced CA-AKI versus conventional PCI (RR 0.27; 95% CI 0.13-0.56; p=0.0004).
- Need for dialysis, all-cause mortality, and major adverse cardiovascular events were not significantly reduced (RR 0.33, 0.48, and 0.52, respectively; all p>0.16).
📋 Practice Implication: Contrast minimization should be a central procedural strategy for CKD patients undergoing PCI; this analysis supports fewer CA-AKI events without establishing reductions in dialysis, mortality, or MACE.
|
Renal failure (2025) - Randomized controlled trial
Key Findings
- CI-AKI incidence was 10.3% with low-dose tolvaptan plus hydration versus 23.3% with hydration alone (p=0.008).
- Creatinine and cystatin C increases were smaller and eGFR decline was less with tolvaptan (p<0.05).
- Six-month MACE incidence did not differ significantly between groups (93.9% vs 88.6%; p=0.142).
📋 Practice Implication: Low-dose tolvaptan may reduce CA-AKI in selected high-risk coronary patients when paired with hydration, but its renal benefit should not be interpreted as proven six-month cardiovascular benefit.
|
|
💡
Summary
Recent high-significance evidence supports a hydration-centered, contrast-sparing approach to contrast-associated acute kidney injury (CA-AKI): ultra-low-contrast PCI substantially reduced CA-AKI in patients with chronic kidney disease, while routine oral or intravenous N-acetylcysteine showed no benefit. Nicorandil and low-dose tolvaptan reduced CA-AKI in selected coronary-intervention populations, but the tolvaptan trial did not demonstrate a significant six-month difference in major adverse cardiovascular events and hard outcomes were not consistently improved.
|
|